Summary of SMC product assessment decisions

The Scottish Medicines Consortium (SMC) has announced its decision on the following therapies:

 Accepted for use
  • Formoterol Easyhaler for asthma and COPD.
  • Lucentis (ranibizumab) for wet AMD.
  • Neupro (rotigotine) patches for early PD.
  • Prezista (darunavir) for adult HIV patients.
  • Symbicort SMART (budesonide + formoterol) for adults with asthma.

Accepted for restricted use, conditions apply:

  • Byetta (exenatide) for type 2 diabetes with metformin and/or sulphonylureas.
  • Medikinet XL (methylphenidate) for ADHD.
  • Noxafil (posaconazole) for prophylaxis of invasive fungal infections in immunocompromised patients.
  • Emselex (darifenacin) for overactive bladder syndrome.
  • Singulair Paediatric (montelukast) for children aged 2—14 years with mild persistent asthma.
 Rejected for use
  • Aldara (imiquimod) for actinic keratoses. 
  • Sutent (sunitinib) for advanced and/or metastatic renal cell carcinoma. 
  • Tarceva (erlotinib) for metastatic pancreatic cancer.
  • Zevalin (ibritumomab) for follicular B-cell non-Hodgkin’s lymphoma.
  • Zibor (bemiparin) for all indications.
  • Avastin (bevacizumab) with paclitaxel for metastatic breast cancer.
  • Herceptin (trastuzumab) with an aromatase inhibitor for metastatic breast cancer.

Further information:

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus